- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Tuesday, Ligand Pharmaceuticals Inc (LGNZZ:PKC) closed at 0.13, 30.00% above the 52 week low of 0.10 set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.13 |
---|---|
High | 0.13 |
Low | 0.13 |
Bid | -- |
Offer | -- |
Previous close | 0.13 |
Average volume | 2.87k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 28 2024 19:00 BST.
More ▼